Pharma News
EMS proposes merger with Hypera to form Brazil's largest drugmaker
On 21 October 2024, Brazilian pharmaceutical giant EMS proposed a partnership with competitor Hypera Pharma, setting a course to become Brazil’s largest drug manufacturer.
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
On 31 October 2024, it was announced that Chicago-based Meitheal Pharmaceuticals had expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co, to market and distribute three biosimilars in the US. These include the oncology biosimilars pegfilgrastim and filgrastim, as well as fertility treatment follitropin alpha.
Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206
In October 2024, China based Bio-Thera Solutions (Bio-Thera) and Hungary’s Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to Johnson & Johnson’s Stelara (ustekinumab).
Advances for Biocon Biologics’ Stelara and Eylea biosimilars
Biocon Biologics (Biocon) settled patent disputes with Janssen to commercialize Bmab 1200, a biosimilar of Stelara (ustekinumab), in several markets, including Europe and Canada. Additionally, Biocon received UK marketing authorization for Yesafili, its biosimilar of Eylea (aflibercept).
China’s Hasten Biopharma acquires 14 products from Celltrion
In July 2024, it was announced that China’s Hasten Biopharmaceutical has acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Korea’s Celltrion.
Coherus sells adalimumab biosimilar Yusimry to HKF for US$40 million amid oncology focus
On 27 June 2024, Coherus BioSciences announced that is has divested Yusimry (aflibercept-jbvf), an adalimumab biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend Industrial (HKF) in a US$40 million deal.
Biocon and Biomm forge alliance to bring semaglutide diabetes treatment to Brazil
By mid-April 2024, India-based Biocon Biologics signed an exclusive licensing and supply agreement that will allow Brazil’s Biomm SA to commercialise semaglutide, which is used to control type-2 diabetes in adults and has been repurposed for obesity management.
Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements
In May 2024, Klinge Biopharma announced an exclusive licensing and supply agreement with MS Pharma for FYB203 commercialization in the Middle East and North Africa (MENA) region. Previously, in April 2024, mAbxience and Teva Pharmaceuticals signed a strategic licensing agreement for a biosimilar candidate for oncology treatment.
Celltrion wins Peruvian public tenders for biosimilar infliximab and trastuzumab
In early May 2024, Celltrion reported that two of its biosimilar products, infliximab and trastuzumab, won the public tender in Peru, further expanding their prescription availability in Peru and solidifying their position in the broader Latin American pharmaceutical market.
Bio-Thera and SteinCares sign agreement to market two biosimilars in LATAM
Bio-Thera Solutions (Bio-Thera) announced in March 2024 a licensing agreement with SteinCares to market two biosimilars in Brazil and the rest of the region.
